CHINA ISOTOPE & RADIATION CORPORATION
中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

ANNOUNCEMENT

PROFIT WARNING

This announcement is made by China Isotope & Radiation Corporation (the "**Company**", together with its subsidiaries referred to as the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**") and the Inside Information Provisions (as defined under the Hong Kong Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company and potential investors that, based on a preliminary review on the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 and information currently available, the revenue is expected to be approximately RMB6,979 million to RMB7,206 million, representing a year-on-year decrease of approximately 5% to 8%; the net profit is expected to be approximately RMB611 million to RMB655 million, representing a year-on-year decrease of approximately 25% to 30%; and the profit for the year attributable to equity shareholders of the Company is expected to be approximately RMB302 million to RMB322 million, representing a year-on-year decrease of approximately 20% to 25% as compared with those for the same period in 2024. Currently, the Company is in normal business operations. The decrease in revenue for the year of 2025 is mainly due to the decline in the revenue of the nuclear medical equipment segment of the Group, while the decrease in profit is mainly due to the effect of supplementary tax payment and late fees of Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., a subsidiary of the Company.

The Company is in the process of finalising the Group's consolidated results for the year ended 31 December 2025. The information contained in this announcement is only based on the unaudited consolidated management accounts of the Group and the information currently available to the Board, which have not been reviewed or audited by the Company's auditors or the Audit and Risk Management Committee of the Board. The actual results of the Group for the year ended 31 December 2025 may differ from the information contained in this announcement. The announcement of the Group's annual results for the year ended 31 December 2025 is expected to be published by the end of March 2026.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 12 February 2026

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.